Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Physiomics (RVW1) Stock Price & Analysis

0 Followers

RVW1 Stock Chart & Stats

€0.01€0.00(0.00%)
At close: 1:00 AM GMT+1
€0.025€0.05€0.075€0.1Jan 15Jul 30Dec 23Jun 21Dec 13
Day’s Range
EUR 0.00 - EUR 0.01
52-Week Range
EUR 0.00 - EUR 0.02
Previous Close
EUR 0.01
Volume
N/A
Average Volume (3M)
67
Market Cap
EUR 2.38M
Enterprise Value
EUR 1.42M
Total Cash (Recent Filing)
EUR 418.63K
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
2.30
Next Earnings
Mar 11, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialist Computational Modelling Offering

The company provides specialist systems biology and pharmacology modelling rather than undifferentiated services. This technical focus can support durable client value by helping drug developers interpret data, understand disease mechanisms, and predict drug behaviour.

Low Leverage

Minimal borrowing limits direct debt and refinancing pressure, giving the company a comparatively less leveraged balance sheet. This provides some financial resilience and preserves flexibility to allocate available funding toward operations despite ongoing losses.

Broad Life-sciences Customer Relevance

Serving biotechnology, pharmaceutical, and research customers gives the modelling offering relevance across multiple parts of the life-sciences ecosystem. That breadth can support recurring demand for analytical expertise as clients advance programs through development.

Bears Say

Persistent Unprofitable Operations

The business has not demonstrated that revenue covers direct and operating costs, with losses persisting across the reported period. Continued negative profitability weakens internally generated capital, limits self-funded growth, and raises pressure to secure further funding.

Sustained Cash Burn

Recurring operating and free-cash-flow outflows show that the company currently consumes cash to support its operations. This reduces financial flexibility and means future activity remains dependent on improving economics or obtaining ongoing external funding.

Deteriorating Recent Revenue Trend

A sharp latest-period revenue decline combined with worsening losses indicates weakening recent operating momentum, not merely a margin issue. If sustained, lower revenue would make it harder to absorb fixed costs, finance development, and move toward profitability.

Physiomics News

RVW1 FAQ

What was Physiomics’s price range in the past 12 months?
Physiomics lowest stock price was €0.00 and its highest was €0.02 in the past 12 months.
What is Physiomics’s market cap?
Physiomics’s market cap is €2.38M.
When is Physiomics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Physiomics’s earnings last quarter?
Physiomics released its earnings results on Oct 13, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Physiomics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Physiomics pay dividends?
Physiomics does not currently pay dividends.
What is Physiomics’s EPS estimate?
Physiomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics have?
Physiomics has 467,208,700 shares outstanding.
What happened to Physiomics’s price movement after its last earnings report?
Physiomics reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Physiomics?
Currently, no hedge funds are holding shares in DE:RVW1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology